| dc.contributor.author | FOCUS Trial Collaboration | |
| dc.date.accessioned | 2019-01-23T16:10:06Z | |
| dc.date.available | 2019-01-23T16:10:06Z | |
| dc.date.issued | 2019-01-19 | |
| dc.identifier.citation | FOCUS Trial Collaboration 2019 , ' Effects of fluoxetine on functional outcomes after acute stroke (FOCUS) : a pragmatic, double-blind, randomised, controlled trial ' , The Lancet , vol. 393 , no. 10168 , pp. 265-274 . https://doi.org/10.1016/S0140-6736(18)32823-X | en |
| dc.identifier.issn | 0140-6736 | |
| dc.identifier.other | PURE: 141182518 | |
| dc.identifier.other | PURE UUID: d49afdcc-a4a2-4218-a89f-1c7811abd3e1 | |
| dc.identifier.other | PubMed: 30528472 | |
| dc.identifier.other | Scopus: 85060034267 | |
| dc.identifier.other | ORCID: /0000-0003-2115-8184/work/54384521 | |
| dc.identifier.uri | http://hdl.handle.net/2164/11823 | |
| dc.description | The start-up phase of the FOCUS trial was funded by the UK Stroke Association (TSA 2011101) and the main phase funded by the NIHR Health Technology Assessment Programme (project number 13/04/30). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NIHR Health Technology Assessment Programme. Recruitment and follow-up was supported by the NIHR-funded UK Stroke Research Network and the Scottish Stroke Research Network, which was supported by NHS Research Scotland (NRS). The study protocol and statistical analysis plan have been published.5, 6 A fully anonymised trial dataset with individual participant data and a data dictionary will be made available to other researchers after the publication of the full trial report in the Health Technology Assessment journal in 2019. Requests should first be directed to Martin Dennis (Co-Chief Investigator). Written proposals will be assessed by the FOCUS trial team and a decision made about the appropriateness of the use of data. A data sharing agreement will be put in place before any data will be shared. | en |
| dc.format.extent | 10 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | The Lancet | en |
| dc.rights | https://creativecommons.org/licenses/by-nc-nd/4.0/ | en |
| dc.subject | Administration, Oral | en |
| dc.subject | Aged | en |
| dc.subject | Antidepressive Agents, Second-Generation/administration & dosage | en |
| dc.subject | Depression/epidemiology | en |
| dc.subject | Double-Blind Method | en |
| dc.subject | Female | en |
| dc.subject | Fluoxetine/administration & dosage | en |
| dc.subject | Fractures, Bone/chemically induced | en |
| dc.subject | Humans | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Recovery of Function | en |
| dc.subject | Stroke Rehabilitation/methods | en |
| dc.subject | Surveys and Questionnaires | en |
| dc.subject | R Medicine | en |
| dc.subject | Medicine(all) | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | 13/04/30 | en |
| dc.subject | Supplementary Data | en |
| dc.subject.lcc | R | en |
| dc.title | Effects of fluoxetine on functional outcomes after acute stroke (FOCUS) : a pragmatic, double-blind, randomised, controlled trial | en |
| dc.type | Journal article | en |
| dc.contributor.institution | University of Aberdeen.Medical Sciences - Cardiovascular Group | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.description.status | Peer reviewed | en |
| dc.description.version | Publisher PDF | en |
| dc.identifier.doi | https://doi.org/10.1016/S0140-6736(18)32823-X | |
| dc.identifier.vol | 393 | en |
| dc.identifier.iss | 10168 | en |
